Burkina Faso vs Euro area: Access to anti-retroviral drugs, female
Burkina Faso
98.0%
in 2024
Euro area
88.6%
in 2022
Burkina Faso rank
1st
Euro area rank
2nd
Access to anti-retroviral drugs, female over time
- Burkina Faso
- Euro area
How they compare
Burkina Faso currently reports 98.0% against 88.6% in Euro area, a difference of 9.4%.
That makes Burkina Faso's figure about 1.1 times Euro area's.
The two have swapped places 3 times across 23 shared years of data; in 2000 it was Euro area ahead.
Burkina Faso ranks 1st and Euro area ranks 2nd of 141 countries.
Across the 3 decades both report, Burkina Faso averaged higher in 1 and Euro area in 2.
Head to head by decade
| Decade | Burkina Faso | Euro area | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.1% | 59.4% | 49.3% | Euro area |
| 2010s | 67.6% | 81.4% | 13.8% | Euro area |
| 2020s | 88.7% | 87.5% | 1.2% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Burkina Faso or Euro area?
- Burkina Faso, at 98.0% against 88.6% in Euro area as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Burkina Faso and Euro area?
- 9.4%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Euro area?
- 23 years are reported by both, from 2000 to 2022.
- How do Burkina Faso and Euro area rank globally for access to anti-retroviral drugs, female?
- Burkina Faso ranks 1st and Euro area ranks 2nd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.